纳武利尤单抗联合或不联合纳武利尤单抗加伊匹木单抗作为免疫治疗强化在转移性肾细胞癌患者中的定制免疫治疗策略(TITAN-RCC):一项多中心、单臂、2期试验
TITAN-RCC是一项多中心单臂2期试验,评估纳武利尤单抗单药诱导后无应答者加用纳武利尤单抗联合伊匹木单抗强化治疗在转移性透明细胞肾细胞癌中的疗效与安全性。一线组确认客观缓解率为36%(90% CI 28-44,p=0.0080),二线组为32%(24-40,p=0.083)。作者认为一线患者中该策略较CheckMate-025中纳武利尤单抗单药显著改善客观缓解率,但总疗效似乎劣于已获批的 upfront 纳武利尤单抗联合伊匹木单抗;二线治疗中,纳武利尤单抗联合伊匹木单抗可作为经获批纳武利尤单抗单药进展后的挽救策略。
要点
- 一线组确认客观缓解率36%(90% CI 28-44,p=0.0080),二线组32%(24-40,p=0.083)。
- 第8或16周纳武利尤单抗确认缓解:一线组31/109(28%),二线组18/98(18%)。
- 最常见3-4级治疗相关不良事件为脂肪酶升高15/207(7%)、结肠炎13/207(6%)、腹泻13/207(6%)。
核心结论
- 在未经治疗的患者中,纳武利尤单抗诱导联合或不联合纳武利尤单抗加伊匹木单抗强化较CheckMate-025中报告的纳武利尤单抗单药显著改善客观缓解率。
- 然而,与已获批的 upfront 纳武利尤单抗联合伊匹木单抗相比,总疗效似乎劣于后者。
- 对于二线治疗,纳武利尤单抗联合伊匹木单抗可作为经获批纳武利尤单抗单药进展后的挽救策略。
研究设计与样本
- TITAN-RCC为多中心、单臂、2期试验,在欧洲8个国家(奥地利、比利时、捷克共和国、法国、德国、意大利、西班牙和英国)的28家医院和癌症中心开展。
- 纳入年龄≥18岁、组织学确诊的中危或低危透明细胞转移性肾细胞癌患者,包括未经治疗(一线人群)或既往接受过一种系统治疗(抗血管生成药物或替西罗莫司;二线人群)。
- 患者须Karnofsky体能状态评分至少70,且按RECIST 1.1有可测量病灶。
- 患者起始接受静脉纳武利尤单抗240 mg每2周一次;第8周早期进展或第16周无应答者接受两或四剂静脉纳武利尤单抗(3 mg/kg)联合伊匹木单抗(1 mg/kg)强化(每3周一次),应答者继续静脉纳武利尤单抗240 mg每2周一次,但后续进展时可接受两至四剂纳武利尤单抗联合伊匹木单抗强化。
- 主要终点为全分析集中经研究者评估的确认客观缓解率,全分析集包括所有接受至少一剂研究药物的患者;安全性也在该人群中评估。
主要发现
- 2016年10月28日至2018年11月30日共入组207例患者,均接受纳武利尤单抗诱导治疗(一线组109例,二线组98例)。
- 207例患者中女性60例(29%),男性147例(71%);中危转移性肾细胞癌147例(71%),低危51例(25%)。
- 中位随访27.6个月(IQR 10.5-34.8)后,一线组109例中39例(36%,90% CI 28-44;p=0.0080)达到确认客观缓解,二线组98例中31例(32%,24-40;p=0.083)达到确认客观缓解。
- 第8或16周纳武利尤单抗确认缓解见于一线组31/109例(28%)和二线组18/98例(18%)。
- 最常见的3-4级治疗相关不良事件(≥5%患者报告)为脂肪酶升高15/207例(7%)、结肠炎13/207例(6%)、腹泻13/207例(6%);3例死亡被认为与治疗相关,分别由于可能的缺血性卒中、呼吸衰竭和肺炎。
关键数值与推荐
- 主要终点要求客观缓解率超过25%以拒绝原假设并显示改善,依据为关键3期CheckMate-025试验结果。
- 一线组确认客观缓解率36%(90% CI 28-44;p=0.0080),二线组32%(24-40;p=0.083)。
- 第8或16周纳武利尤单抗确认缓解率:一线组28%(31/109),二线组18%(18/98)。
临床怎么用
- 作者认为,在未经治疗的患者中,纳武利尤单抗诱导联合或不联合纳武利尤单抗加伊匹木单抗强化较CheckMate-025中纳武利尤单抗单药显著改善客观缓解率。
- 作者认为,与已获批的 upfront 纳武利尤单抗联合伊匹木单抗相比,总疗效似乎劣于后者。
- 作者认为,对于二线治疗,纳武利尤单抗联合伊匹木单抗可作为经获批纳武利尤单抗单药进展后的挽救策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nivolumab plus ipilimumab is approved as first-line regimen for intermediate-risk or poor-risk metastatic renal cell carcinoma, and nivolumab monotherapy as second-line therapy for all risk groups. We aimed to examine the efficacy and safety of nivolumab monotherapy and nivolumab plus ipilimumab combination as an immunotherapeutic boost after no response to nivolumab monotherapy in patients with intermediate-risk and poor-risk clear-cell metastatic renal cell carcinoma. METHODS: TITAN-RCC is a multicentre, single-arm, phase 2 trial, done at 28 hospitals and cancer centres across Europe (Austria, Belgium, Czech Republic, France, Germany, Italy, Spain, and the UK). Adults (aged ≥18 years) with histologically confirmed intermediate-risk or poor-risk clear-cell metastatic renal cell carcinoma who were formerly untreated (first-line population) or pretreated with one previous systemic therapy (anti-angiogenic or temsirolimus; second-line population) were eligible. Patients had to have a Karnofsky Performance Status score of at least 70 and measurable disease per Response Evaluation Criteria in Solid Tumours (version 1.1). Patients started with intravenous nivolumab 240 mg once every 2 weeks. On early progressive disease (week 8) or non-response at week 16, patients received two or four doses of intravenous nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) boosts (once every 3 weeks), whereas responders continued with intravenous nivolumab (240 mg, once every 2 weeks), but could receive two to four boost doses of nivolumab plus ipilimumab for subsequent progressive disease. The primary endpoint was confirmed investigator-assessed objective response rate in the full analysis set, which included all patients who received at least one dose of study medication; safety was also assessed in this population. An objective response rate of more than 25% was required to reject the null hypothesis and show improvement, on the basis of results from the pivotal phase 3 CheckMate-025 trial. This study is registered with ClinicalTrials.gov, NCT02917772, and is complete. FINDINGS: Between Oct 28, 2016, and Nov 30, 2018, 207 patients were enrolled and all received nivolumab induction (109 patients in the first-line group; 98 patients in the second-line group). 60 (29%) of 207 patients were female and 147 (71%) were male. 147 (71%) of 207 patients had intermediate-risk metastatic renal cell carcinoma and 51 (25%) had poor-risk disease. After median follow-up of 27·6 months (IQR 10·5-34·8), 39 (36%, 90% CI 28-44; p=0·0080) of 109 patients in the first-line group and 31 (32%, 24-40; p=0·083) of 98 patients in the second-line group had a confirmed objective response for nivolumab with and without nivolumab plus ipilimumab. Confirmed response to nivolumab at week 8 or 16 was observed in 31 (28%) of 109 patients in the first-line group and 18 (18%) of 98 patients in the second-line group. The most frequent grade 3-4 treatment-related adverse events (reported in ≥5% of patients) were increased lipase (15 [7%] of 207 patients), colitis (13 [6%]), and diarrhoea (13 [6%]). Three deaths were reported that were deemed to be treatment-related: one due to possible ischaemic stroke, one due to respiratory failure, and one due to pneumonia. INTERPRETATION: In treatment-naive patients, nivolumab induction with or without nivolumab plus ipilimumab boosts significantly improved the objective response rate compared with that reported for nivolumab monotherapy in the CheckMate-025 trial. However, overall efficacy seemed inferior when compared with approved upfront nivolumab plus ipilimumab. For second-line treatment, nivolumab plus ipilimumab could be a rescue strategy on progression with approved nivolumab monotherapy. FUNDING: Bristol Myers Squibb.
引用
- Grimm MO, Esteban E, Barthélémy P, et al. Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2023. PMID: 37844597. doi:10.1016/S1470-2045(23)00449-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。